Church of PeptidesSearch
Investigational combination · Human trial evidence

CagriSema

Two ingredients. Six clinical chapters. No missing footnotes.

Follow Patient One through the human CagriSema trials, the safety record, a failed comparison endpoint and the distinction between filing and approval.

Journey published November 3, 2026 · Evidence reviewed 2026-11-03

Start at the beginning →Where we are today
  1. 01Two ingredients, one questionHuman phase 2 · 2021 enrollment; 2023 publication
  2. 02The number needs its footnoteHuman phase 3a · REDEFINE 1; published June 22, 2025
  3. 03The page nobody gets to removeHuman phase 3a · REDEFINE 1 safety; June 22, 2025
  4. 04A different room, a different populationHuman phase 3a · REDEFINE 2; published June 22, 2025
  5. 05The rival gets the same clockHuman phase 3 · REDEFINE 4; sponsor results February 23, 2026
  6. 06The stamp still mattersRegulatory and evidence checkpoint · Reviewed November 3, 2026
Today’s checkpoint

November 3, 2026 review: six linked clinical episodes; the latest verified sponsor status (October 29) remains investigational. Weight-loss findings, serious harms and the unsuccessful REDEFINE 4 endpoint stay together.

Open the medicine’s evidence profile · Other journeys

Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.